BCM-0241
VRE (Vancomycin-resistant Enterococcus) infection
Key Facts
About Biocidium Biopharmaceuticals
Biocidium Biopharmaceuticals is a private, clinical-stage biotech company founded in 2006, developing novel antibiotics and antifungals to combat serious multi-drug resistant infections. The company leverages a significant IP portfolio to advance a pipeline of pre-clinical candidates targeting pathogens like MRSA, VRE, and CRE, while also exploring applications in dermatology and oncology. Operating in the high-need but challenging anti-infectives market, Biocidium's strategy is to provide comprehensive, bio-based solutions against resistant gram-positive and gram-negative bacteria and fungi. Its success hinges on advancing its lead candidates through clinical development and navigating the complex regulatory and commercial landscape for new antibiotics.
View full company profile